Navigation Links
Progeria: Promising results from new gene therapy on animals
Date:10/27/2011

Researchers are continuing their efforts in an attempt to counter the consequences of the genetic defect that causes Progeria. Until now, no model had been able to accurately imitate the effects of the disease in humans. For several years, research has been conducted in close collaboration from teams led by Nicolas Lvy and Annachiara De Sandre-Giovannoli at Inserm/Universit de la Mditerrane and from a team led by Carlos Lpez-Otn (University of Oviedo) and has succeeded in making such a model possible. The lifespan of mice treated through gene therapy is significantly extended and several other parameters related to them are improved.

The research, published on 26 October 2011 in Science Translational Medicine, received backing from the AFM thanks to donations from a Telethon.

Progeria is a rare genetic disease. Children suffering from it seem to experience accelerated aging (chronic hair loss, joint pains, thin and hairless skin, cardiovascular problems). In 2003, Nicolas Lvy and his team identified the cause of the disease when they discovered the involvement of the LMNA (nuclear protein-coding) gene, lamin A/C. The mutation causes the production of a truncated protein, progerin, which accumulates in the nuclei of cells and its toxic effects cause their deformation and various other malfunctions. It has since been proven that progerin progressively accumulates in normal cells, thus establishing a link between the disease and physiological aging.

In 2008, European clinical trials began on twelve children suffering from Progeria. The treatment is based on a combination of two existing molecules: statins (prescribed in the treatment and prevention of atherosclerosis and cardiovascular risks) and aminobisphosphonates (prescribed in to treat osteoporosis and to prevent complications in some forms of cancer). The use of both these molecules aims to chemically alter progerin to reduce its toxicity. However, although this treatmen
'/>"/>

Contact: Priscille Rivire
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New method of growing high-quality graphene promising for next-gen technology
2. Study finds promising drug treatment for improving language, social function in people with autism
3. Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome
4. Researcher tests promising drug on those with Down syndrome
5. Exonhit and BGI announce successful completion of a promising next-generation sequencing project
6. Grants awarded to help bring promising bioscience discoveries to market
7. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
8. 22 of Americas most promising scientists selected as 2011 Pew Scholars in the Biomedical Sciences
9. A promising new approach to autoimmune diseases
10. Several abstracts on gout reveal true burden of disease and highlight promising new treatments
11. Celiac disease vaccine shows promising results in Phase I trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... pandemic risk from strains of influenza virus increases with ... to become complacent that the most substantial threats have ... Influenza pandemics arise when a new virus strain – ... – spreads in the human population. There have been ... worst of which – the 1918 Spanish Flu – ...
(Date:10/15/2014)... German Gauß-Allianz has admitted Johannes Gutenberg University Mainz ... Rhineland-Palatinate science hub continues to maintain a significant ... , "The acceptance of Johannes Gutenberg University ... is a milestone in the national and international ... The state of Rhineland-Palatinate can be proud that ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... Coral reefs are among the most diverse ecosystems ... Bird,s nest coral ( Seriatopora hystrix ) is common ... a range of depths. However, there is little gene ... even the algal endosymbionts (Symbiodinium), which provide energy for ...
... - For the first time, researchers have found a way ... directly into a single living cell without a needle. ... through a tiny channel and into a cell in a ... colleagues at Ohio State University describe the technique in the ...
... number of areas in the human genetic code that are ... in a new study of over 61,000 people, published today ... is an international collaboration led by Imperial College London and ... of which had not been linked to liver function before. ...
Cached Biology News:Deep-reef coral hates the light, prefers the shade 2Researchers do precise gene therapy without a needle 2Researchers do precise gene therapy without a needle 3Largest ever genetic study of liver function could point the way to new treatments 2
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... than half-a-century ago, the Dutch theoretical physicist Hendrik Casimir ... a vacuum would attract. The mysterious force arises from ... of existence, as described by quantum theory. Now Norio ... Japan, has predicted that in certain circumstances a reversal ...
... Life Sciences, Inc. (NASDAQ: SRLS ), a ... to facilitate the discovery, development and production of human ... of shareholders held today, its shareholders voted to adopt ... Project Plasma Merger Corp., affiliates of Linden Capital Partners. ...
... April 17, 2012 Senior clinical ... Shire and GSK, met recently at the US ... and define competencies for a global competition to ... South America. The US Clinical Researcher ...
Cached Biology Technology:SeraCare Shareholders Approve Acquisition by Linden Capital Partners 2SeraCare Shareholders Approve Acquisition by Linden Capital Partners 3Quality Standards Established for Competition to Identify Best Researchers in the US 2
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... and Protein G bind specifically to Fc ... and Protein G conjugates are commonly used ... and immunoglobulin subtypes from serum, hybridoma ascites ... fluids. These reagents are also commonly used ...
... dishes with stacking feature for easy storage. Linkage: ... created to easily match Cornings product number. If ... old Sigma-Aldrich number (Z70,947-6) or contact customer service ... Comp Dim: surface area 55 cm 2 ...
... thermal cycler blocks, 96-well PCR plate, 0.3ml maximum ... seals), Cut-away corner , Fits all 0.2ml thermal ... capillary sequencers, Clear well bottom for sample visibility, ... Films and Foils, Heat Seals and Flat and ...
Biology Products: